Drug Information

General Information
Drug ID
DR00046
Drug Name
Levofloxacin
Synonyms
(-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate; (-)-Ofloxacin; (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; (R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (R)-isomer; (S)-(-)-Ofloxacin; (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (S)-Ofloxacin; Aeroquin; Cravit; Cravit (TN); Cravit Ophthalmic; D-Levofloxacin; DR 3354; DR-3355; DR-3355: L-isomer of ofloxacin; DR3355; Elequine; Floxacin; Floxel; HR 355; HR-355; Iquix; Iquix (TN); L-Ofloxacin; LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER; LFX; LVX; Leroxacin; Lesacin; Levaquin; Levaquin (TN); Levofloxacin (INN); Levofloxacin [USAN:INN:JAN]; Levofloxacin tablet, suspension or intravenous; Levofloxacine; Levofloxacine [INN-French];Levofloxacino [INN-Spanish]; Levofloxacino; Levofloxacinum; Levofloxacinum [INN-Latin]; Levokacin; Levox; Levoxacin; MP-376; Mosardal; Nofaxin; Ofloxacin; Ofloxacin S-(-)-form; Oftaquix; Oftaquix (TN); Quixin; Quixin (TN); R-Ofloxacin; RWJ 25213-097; RWJ-25213; Reskuin; S-(-)-Ofloxacin; Tavanic; Tavanic (TN); Volequin
Drug Type
Small molecular drug
Indication Gram-positive & negative bacteria infections [ICD11: 1A00-1H0Z] Approved [1]
Therapeutic Class
Antibiotics
Structure
3D MOL 2D MOL
Formula
C18H20FN3O4
Canonical SMILES
CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
InChI
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
InChIKey
GSDSWSVVBLHKDQ-JTQLQIEISA-N
CAS Number
CAS 100986-85-4
Pharmaceutical Properties Molecular Weight 361.4 Topological Polar Surface Area 73.3
Heavy Atom Count 26 Rotatable Bond Count 2
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 8
XLogP
-0.4
PubChem CID
149096
PubChem SID
10250227 , 103165325 , 104052737 , 104179033 , 104253435 , 11364613 , 11367175 , 11369737 , 11372008 , 11374743 , 11377899 , 11485627 , 11489492 , 11490810 , 11492937 , 11495533 , 11528725 , 12014081 , 14876841 , 14901428 , 24857060 , 26612693 , 26680408 , 26719895 , 46225907 , 46386771 , 46505134 , 48185231 , 48334772 , 49665952 , 49681682 , 50064059 , 50123181 , 56314311 , 57346857 , 57648297 , 598046 , 76034622 , 7979773 , 85261747 , 85789483 , 87558890 , 89736102 , 92124751 , 92307928 , 92308354 , 92309286 , 92710579 , 96024810 , 9862
ChEBI ID
ChEBI:63598
TTD Drug ID
D02RSN
DT(s) Transporting This Drug OATP1A2 Transporter Info Organic anion transporting polypeptide 1A2 Substrate [2]
P-GP Transporter Info P-glycoprotein 1 Substrate [3]
Drug-Transporter Activity Data
Drug-Transporter Activity Data OATP1A2 Transporter Info Km = 136 microM Oocytes-OATP1A2 [2]
P-GP Transporter Info Km = 5600 microM Human enterocyte-like 2 cells (Caco-2)-MDR1 [4]
P-GP Transporter Info Km = 3000 microM LLC-PK1 cells-MDR1 [5]
References
1 Levofloxacin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
3 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
4 Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2. J Pharmacol Exp Ther. 2000 Oct;295(1):360-6.
5 Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.